Argenx SE (ARGX)
| Market Cap | 15.17B |
| Revenue (ttm) | 44.42M |
| Net Income (ttm) | -645.03M |
| Shares Out | 51.40M |
| EPS (ttm) | -6.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,795 |
| Open | 295.99 |
| Previous Close | 296.02 |
| Day's Range | 293.15 - 298.35 |
| 52-Week Range | 244.98 - 382.15 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 346.76 (+17.9%) |
| Est. Earnings Date | Oct 28, 2021 |
About ARGX
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indic...
Financial Performance
In 2020, Argenx SE's revenue was 36.43 million, a decrease of -47.80% compared to the previous year's 69.78 million. Losses were -528.92 million, 224.6% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 17 analysts, the average rating for Argenx SE stock is "Buy." The 12-month stock price forecast is 346.76, which is an increase of 17.88% from the latest price.
News
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
October 21 , 202 1 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,...
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers...
argenx to Present at Upcoming Investor Conferences
September 3, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, ...
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myastheni...
Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...
Recap: argenx Q2 Earnings
Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not co...
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...
argenx to Host Virtual R&D Day on July 20, 2021
July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthen...
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop th...
argenx to regain global rights to cusatuzumab
Regulated Information/Inside Information
argenx Appoints Karl Gubitz as Chief Financial Officer
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...
argenx to Present at Upcoming Investor Conferences
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...
Recap: argenx Q1 Earnings
Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimat...
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)
argenx's Earnings Outlook
argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.
argenx announces results of Annual General Meeting of Shareholders
May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today ...
argenx Management to Present at Upcoming Virtual Investor Conferences
April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...
argenx announces Annual General Meeting of Shareholders on May 11, 2021
March 30, 2021
argenx: Q4 Earnings Insights
Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the es...
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)